论文部分内容阅读
2016年4月29日,由Acadia制药公司研发的匹莫范色林(pimavanserin tartrate)经FDA批准上市,商品名为Nuplazid。该药为首个用于治疗帕金森患者幻觉和妄想并发症的新药[1],推荐剂量为每天一次口服两片(17 mg)。Pimavanserin tartrate的中文化学名称:N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-[[4-(2-甲基丙氧基)苯基]甲
On April 29, 2016, pimavanserin tartrate developed by Acadia Pharmaceuticals was approved by the FDA under the trade name Nuplazid. The drug is the first of its kind used to treat hallucinations and delusions complications in Parkinson’s patients [1]. The recommended dose is two tablets (17 mg) orally once daily. Chinese chemical name of Pimavanserin tartrate: N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N’- [4- (2- methylpropoxy) phenyl A